Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue 4, 1997, Pages 633-638

  Galindo Rodriguez, Griselda ^a,b   Avina Zubieta, J Antonio ^a   Fitzgerald, Avril ^a   LeClerq, Sharon A ^a   Russell, Anthony S ^a,c   Suarez Almazor, Maria E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Faculty of Medicine   (Papua New Guinea)

^c Division of Rheumatology   (United States)

Author keywords

Patterns of practice; Rheumatoid arthritis; Second line therapy

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AURANOFIN; FEMALE; GOLD; HUMANS; MALE; METHOTREXATE; PENICILLAMINE; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATOLOGY; SULFASALAZINE;

EID: 0031003199     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Smyth CJ: Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med 1972;51:31-9.
2. Felson DT, Anderson JJ, Meenan RF: Use of short-term efficacy/toxicity trade-offs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
3. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA: Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
4. Prashker MJ, Meenan RF: The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
5. Suarez-Almazor ME, Jacobs P: A comparative study of the cost-effectiveness of various second-line drugs for the treatment of rheumatoid arthritis (RA) (abstr). Arthritis Rheum 1995;(suppl)38:S225.
6. Bellamy N, Brooks PM: Current practice in antimalarial drug prescribing in rheumatoid arthritis. J Rheumatol 1986;13:551-5.
7. Kay EA, Pullar T: Variation among rheumatologists in prescribing and monitoring of disease modifying antirheumatoid drugs. Br J Rheumatol 1992;31:477-83.
8. Criswell LA, Redfearn WJ: Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum 1994;37:476-80.
9. Pincus T, Marcum SB, Callahan LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology practices. II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
10. Suarez-Almazor ME, Soskolne CL, Saunders D, Russell AS: Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43.
11. Suarez-Almazor ME, Kendall CJ, Skeith K: Treating patients with rheumatoid arthritis. Beliefs and preferences of Canadian rheumatologists (abstr). Arthritis Rheum 1994;(suppl 9)37:S229.
12. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Hawley D, Wolfe F: Are the results of controlled clinical trials and observational studies of second-line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcomes: An analysis of 122 studies. J Rheumatol 1991;18:1008-14.
14. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 1990;33:1449-61.
15. Felson DT, Anderson JJ, Chernoff M, Meenan RF: The comparative efficacy of cyclosporine (CS) and other second-line drugs in rheumatoid arthritis (RA): Update of a meta-analysis (abstr). Arthritis Rheum 1995;38:S283.
16. Suarez-Almazor ME, PANLAR Clinical Epidemiology Group: Use of second line (2-line) drugs in patients with rheumatoid arthritis in various PANLAR countries (abstr). Arthritis Rheum 1995;(suppl)38:S368.
17. Rush PJ, Shore A: Physician perceptions of the value of physical modalities in the treatment of musculoskeletal disease. Br J Rheumatol 1992;33:566-8.
18. Yelin EH, Shearn MA, Epstein WV: Health outcomes for a chronic disease in prepaid group practice and fee for service settings. Medical Care 1986;24:236-47.
19. Henke CJ, Epstein WV: Practice variation in rheumatologists' encounters with their patients who have rheumatoid arthritis. Medical Care 1991;29:799-812.
20. Liang MH: The study of practice variation in managing rheumatic diseases. Bull Rheum Dis 1994;43:6-8.
21. Criswell LA, Henke CJ: What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-35.
22. Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS: Outcome in rheumatoid arthritis. A 1985 inception cohort study. J Rheumatol 1994;21:1438-46.
23. Van der Heijde D, van Riel P, Nuver-Zwart IH, Gribnau FW, van de Putte LB: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
24. Brown DA, Moreland LW, Alarcon GS: Practice variations in the administration of gold salts for the treatment of rheumatoid arthritis during a 10 year period (abstr). Arthritis Rheum 1992;(suppl)35:S203.
25. Suarez-Almazor ME, Ramos-Remus C, Russell AS: Gold therapy in rheumatoid arthritis: Determinants of response (abstr). Arthritis Rheum 1992;(suppl)35:A236.
26. Rheumatoid Arthritis Clinical Trial Archive Group: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995;22:218-23.
27. Fuchs HA, Kaye JJ, Callahan LF, Pincus T: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
28. Pincus T, Callahan LF, Sale WG, et al: Severe functional declines, work disability, and increase mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
29. Pincus T, Brooks RH: Improved outcomes in rheumatoid arthritis between 1984-1994 compared to previous decades: Evidence from self-audit of rheumatology clinical care using routine patient questionnaires (abstr). Arthritis Rheum 1995;(suppl)38:S366.